Viking Therapeutics (VKTX) Current Assets (2014 - 2026)
Viking Therapeutics (VKTX) posted Current Assets of $517.6 million for Q2 2026, down 14.9% sequentially from $608.2 million in Q1 2026, and down 37.42% YoY from $827.0 million in Q2 2025.
Viking Therapeutics (VKTX) Current Assets (2014 - 2026) Analysis & Trends
Viking Therapeutics has reported Current Assets for 13 years, with the latest figure at $517.6 million in Q2 2026.
- Quarterly Current Assets fell 37.42% year-over-year to $517.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $517.6 million (down 37.42% YoY) and the FY2025 annual result came in at $715.6 million, down 21.12% from the prior year.
- Current Assets fell to $517.6 million in Q2 2026 per VKTX's latest filing, from $608.2 million in the prior quarter.
- Over five years, Current Assets peaked at $966.3 million in Q1 2024 and troughed at $149.5 million in Q1 2023.
- A 5-year average of $557.3 million and a median of $562.9 million in 2026 frame the typical range for Current Assets.
- The sharpest annual moves came in 2024 and 2026: Current Assets soared 546.52% in 2024, then sank 37.42% in 2026.
- Over 5 years, Current Assets stood at $167.0 million in 2022, then soared by 119.84% to $367.2 million in 2023, then jumped by 147.05% to $907.2 million in 2024, then dropped by 21.12% to $715.6 million in 2025, then declined by 27.67% to $517.6 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $517.6 million, $608.2 million, and $715.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Viking Therapeutics | 3.87 Bn | 3.87 Bn | - | 517.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 517.56 Mn |
| Mar 31, 2026 | 608.21 Mn |
| Dec 31, 2025 | 715.60 Mn |
| Sep 30, 2025 | 738.70 Mn |
| Jun 30, 2025 | 827.02 Mn |
| Mar 31, 2025 | 866.02 Mn |
| Dec 31, 2024 | 907.22 Mn |
| Sep 30, 2024 | 936.65 Mn |
| Jun 30, 2024 | 945.72 Mn |
| Mar 31, 2024 | 966.34 Mn |
| Dec 31, 2023 | 367.23 Mn |
| Sep 30, 2023 | 381.30 Mn |
| Jun 30, 2023 | 399.37 Mn |
| Mar 31, 2023 | 149.47 Mn |
| Dec 31, 2022 | 167.04 Mn |
| Sep 30, 2022 | 165.15 Mn |
| Jun 30, 2022 | 179.86 Mn |
| Mar 31, 2022 | 193.30 Mn |
| Dec 31, 2021 | 210.53 Mn |
| Sep 30, 2021 | 224.29 Mn |